LifeStance Health Group, Inc. (LFST) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
↓
41.98
↓-26% vs avg
5yr avg: 56.49
30Y Low33.5·High79.4
P/FCF
↓
31.20
+8% vs avg
5yr avg: 28.82
30Y Low25.0·High32.6
P/B Ratio
↓
2.28
↑+27% vs avg
5yr avg: 1.79
30Y Low1.2·High2.0
ROE
↑
0.7%
↓+106% vs avg
5yr avg: -10.8%
30Y Low-24%·High1%
Debt/EBITDA
↓
2.41
↓-67% vs avg
5yr avg: 7.37
30Y Low2.4·High12.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LFST Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
LifeStance Health Group, Inc. trades at 442.5x earnings, 26% above its 5-year average of 352.0x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 1882%. On a free-cash-flow basis, the stock trades at 31.2x P/FCF, 8% above the 5-year average of 28.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.4B | $2.8B | $2.8B | $2.9B | $1.8B | $3.1B | — | — |
| Enterprise Value | $3.4B | $2.7B | $3.1B | $3.3B | $2.1B | $3.1B | — | — |
| P/E Ratio → | 442.50 | 352.00 | — | — | — | — | — | — |
| P/S Ratio | 2.41 | 1.93 | 2.23 | 2.73 | 2.04 | 4.67 | — | — |
| P/B Ratio | 2.28 | 1.81 | 1.93 | 2.01 | 1.16 | 2.02 | — | — |
| P/FCF | 31.20 | 25.03 | 32.61 | — | — | — | — | — |
| P/OCF | 23.48 | 18.84 | 26.05 | — | 33.25 | 331.00 | — | — |
P/E links to full P/E history page with 30-year chart
LFST EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
LifeStance Health Group, Inc.'s enterprise value stands at 42.0x EBITDA, 26% below its 5-year average of 56.5x. The Healthcare sector median is 14.4x, placing the stock at a 192% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.90 | 2.50 | 3.13 | 2.47 | 4.69 | — | — |
| EV / EBITDA | 41.98 | 33.55 | 79.44 | — | — | — | — | — |
| EV / EBIT | 131.40 | 112.34 | — | — | — | — | — | — |
| EV / FCF | — | 24.53 | 36.47 | — | — | — | — | — |
LFST Profitability
Margins and return-on-capital ratios measuring operating efficiency
LifeStance Health Group, Inc. earns an operating margin of 1.8%. Operating margins have expanded from -17.9% to 1.8% over the past 3 years, signaling improving operational efficiency. ROE of 0.7% is modest. ROIC of 1.2% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.5% | 28.5% | 32.2% | 28.6% | 27.6% | 30.2% | 35.6% | 29.4% |
| Operating Margin | 1.8% | 1.8% | -2.5% | -17.9% | -24.5% | -42.9% | 4.1% | 7.2% |
| Net Profit Margin | 0.7% | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | -10.1% | 2.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 0.7% | 0.7% | -4.0% | -12.6% | -14.1% | -24.2% | -9.2% | — |
| ROA | 0.4% | 0.4% | -2.7% | -8.7% | -10.5% | -17.6% | -4.1% | 2.0% |
| ROIC | 1.2% | 1.2% | -1.3% | -7.6% | -9.2% | -14.8% | 1.8% | — |
| ROCE | 1.3% | 1.3% | -1.7% | -9.7% | -11.0% | -17.3% | 1.8% | 6.8% |
LFST Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
LifeStance Health Group, Inc. carries a Debt/EBITDA ratio of 2.4x, which is manageable (27% below the sector average of 3.3x). The company holds a net cash position — cash of $249M exceeds total debt of $194M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 2.1x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.34 | 0.36 | 0.32 | 0.10 | 0.37 | — |
| Debt / EBITDA | 2.41 | 2.41 | 12.33 | — | — | — | 7.88 | 3.72 |
| Net Debt / Equity | — | -0.04 | 0.23 | 0.30 | 0.24 | 0.01 | 0.35 | — |
| Net Debt / EBITDA | -0.68 | -0.68 | 8.40 | — | — | — | 7.47 | 3.55 |
| Debt / FCF | — | -0.50 | 3.86 | — | — | — | — | 27.74 |
| Interest Coverage | 2.06 | 2.06 | -1.17 | -8.74 | -10.68 | -7.56 | -1.01 | 2.82 |
Net cash position: cash ($249M) exceeds total debt ($194M)
LFST Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.65x means LifeStance Health Group, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.11x to 1.65x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | 1.65 | 1.37 | 1.11 | 1.33 | 2.28 | 1.00 | 0.50 |
| Quick Ratio | 1.65 | 1.65 | 1.37 | 1.11 | 1.33 | 1.96 | 1.00 | 0.50 |
| Cash Ratio | 0.99 | 0.99 | 0.68 | 0.39 | 0.62 | 1.27 | 0.25 | 0.06 |
| Asset Turnover | — | 0.65 | 0.59 | 0.50 | 0.40 | 0.35 | 0.24 | 0.76 |
| Inventory Turnover | — | — | — | — | — | 12.24 | — | — |
| Days Sales Outstanding | — | 24.53 | 38.52 | 43.44 | 43.10 | 54.30 | 42.29 | 32.86 |
LFST Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
LifeStance Health Group, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.2% | 0.3% | — | — | — | — | — | — |
| FCF Yield | 3.2% | 4.0% | 3.1% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Shares Outstanding | — | $391M | $379M | $367M | $355M | $328M | $374M | $374M |
Peer Comparison
Compare LFST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LFSTYou | $3B | 442.5 | 42.0 | 31.2 | 28.5% | 1.8% | 0.7% | 1.2% | 2.4 |
 ACHC | $2B | -2.0 | 8.3 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 |
 UHS | $11B | 7.4 | 6.1 | 12.6 | 90.4% | 11.5% | 21.0% | 12.3% | 2.1 |
 SGRY | $2B | -23.5 | 10.0 | 9.6 | 23.1% | 11.8% | -2.2% | 4.1% | 7.1 |
 OPCH | $3B | 16.3 | 7.4 | 12.6 | 18.1% | 6.0% | 15.2% | 15.3% | — |
 ENSG | $10B | 29.8 | 25.7 | 27.5 | 13.7% | 8.6% | 16.9% | 7.0% | 7.7 |
 TALK | $868M | 129.5 | 137.8 | — | 43.0% | 1.4% | 6.6% | 3.9% | — |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LFST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LFST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LFST vs ACHC
Side-by-side business, growth, and profitability comparison vs Acadia Healthcare Company, Inc..
Start ComparisonLFST — Frequently Asked Questions
Quick answers to the most common questions about buying LFST stock.
What is LifeStance Health Group, Inc.'s P/E ratio?
LifeStance Health Group, Inc.'s current P/E ratio is 442.5x. This places it at the 50th percentile of its historical range.
What is LifeStance Health Group, Inc.'s EV/EBITDA?
LifeStance Health Group, Inc.'s current EV/EBITDA is 42.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 56.5x.
What is LifeStance Health Group, Inc.'s ROE?
LifeStance Health Group, Inc.'s return on equity (ROE) is 0.7%. The historical average is -10.6%.
Is LFST stock overvalued?
Based on historical data, LifeStance Health Group, Inc. is trading at a P/E of 442.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are LifeStance Health Group, Inc.'s profit margins?
LifeStance Health Group, Inc. has 28.5% gross margin and 1.8% operating margin.
How much debt does LifeStance Health Group, Inc. have?
LifeStance Health Group, Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.